Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
Abstract A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures of CYP3A4, CYP2C8, and CYP2B6 substrat...
Main Authors: | Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12605 |
Similar Items
-
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021-12-01) -
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
by: Darcy J. Mulford, et al.
Published: (2023-04-01) -
A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
by: Sebastian G. Wicha, et al.
Published: (2017-12-01) -
PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
by: Jayaprakasam Bolleddula, et al.
Published: (2021-06-01) -
Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
by: Kelly Bleasby, et al.
Published: (2021-08-01)